Panbela Therapeutics (NASDAQ:PBLA) and Acerus Pharmaceuticals (OTCMKTS:TRLPF) Critical Contrast

Institutional & Insider Ownership

4.4% of Panbela Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Acerus Pharmaceuticals shares are owned by institutional investors. 0.0% of Panbela Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Panbela Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Acerus Pharmaceuticals has a beta of 2.6, meaning that its stock price is 160% more volatile than the S&P 500.

Profitability

This table compares Panbela Therapeutics and Acerus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Panbela Therapeutics	N/A	N/A	-302.61%
Acerus Pharmaceuticals	-254.66%	-346.72%	-94.54%

Valuation & Earnings

This table compares Panbela Therapeutics and Acerus Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Panbela Therapeutics	N/A	N/A	-$25.26 million	($71.13)	0.00
Acerus Pharmaceuticals	$7.38 million	7.71	-$18.79 million	($0.08)	-2.75

Acerus Pharmaceuticals has higher revenue and earnings than Panbela Therapeutics. Acerus Pharmaceuticals is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Panbela Therapeutics

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.